Increased degradation of type I collagen in patients with inflammatory bowel disease

Gut

Volumn 38, Issue 2, 1996, Pages 223-228

  Silvennoinen, J ^a,b   Risteli, L ^a   Karttunen, T ^a   Risteli, J ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bone mineral density; ICTP; Inflammatory bowel disease; Osteocalcin; PICP

Indexed keywords

OSTEOCALCIN; PROCOLLAGEN;

ARTICLE; BONE DENSITY; COLLAGEN DEGRADATION; CONTROLLED STUDY; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030060306     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.2.223     Document Type: Article

References (25)

1. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410-5.
2. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Poy Montbrun T, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 9: 1396-403.
3. Silvennoinen J, Karttunen T, Niemelä S, Manelius J, Lehtola J. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
4. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994; 24: 81-94.
5. Elomaa I, Virkkunen P, Risteli I, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992; 66: 337-41.
6. Kylmälä T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish prostate cancer group. Eur J Cancer 1993; 29A: 821-5.
7. Hakala M, Risteli L, Manclius J, Nieminen P, Risteli J. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Du 1993; 52: 866-9.
8. Kotaniemi A, Isomäki H, Hakala M, Risteli L, Risteli J. Increased type I collagen degradation in early rheumatoid arthritis. J Rheumatol 1994; 21: 1593-6.
9. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease. Correlation to bone histomorphometry. J Bone Miner Res 1993; 8: 127-32.
10. Pera A, Bellando P, Caldera D, Ponti V, Astegiano M, Barletti C, et al. Colonoscopy in inflammatory bowel disease: diagnostic accuracy and proposal of an endoscopic score. Gastroenterology 1987; 92: 181-5.
11. Chong SKF, Blackshaw AJ, Boyle S, Williams CB, Walker-Smith JA. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut 1985; 26: 55-9.
12. Rutegard I, Ahsgren L, Stenling K, Nilsson T. A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology 1990; 37 (suppl 2P): 110-2.
13. The Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended methods for the determination of four enzymes in blood. Scand J Clin Invest 1974; 33: 291-306.
14. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-40.
15. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328-32.
16. Kröger H, Laitinen K. Bone mineral density measured by dual-energy X-ray absorptiometry in normal men. Ear J Clin Invest 1992; 22: 454-60.
17. Kroger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. Osteoporosis Int 1992; 2; 135-40.
18. Välimäki MJ, Kärkkäinen M, Lamberg-Allardt C, Laitinen K, Alhava E, Heikkinen J, et al. Exercise, smoking and calcium intake during adolescence and early adulthood as determinants of peak bone mass. BMJ 1994; 309: 230-5.
19. Pietschmann P, Konflach P, Wolosczczuk W. Increased serum osteocalcin levels in patients with lactase deficiency. Am J Gastroenterol 1991; 86: 72-4.
20. Haukipuro K, Melkko J, Risteli L, Kairaluoma MI, Risteli J. Synthesis of type I collagen in healing wounds in humans. Ann Surg 1991; 213: 76-80.
21. Oikarinen A, Auito P, Kiistala U, Risteli L, Risteli J. A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical glucocorticoid treatment. J Invest Dermatol 1992; 98: 220-5.
22. Jensen LT, Olesen HP, Risteli J, Lorenzen I. External thoracic duct-venous shunt in conscious pigs for long term studies of connective tissue metabolites in lymph. Lab Anim Sci 1990; 40: 620-4.
23. Kjeldsen J, Junker H, Scaffalitzky de Muckadell OB. Evidence that collagen I turnover is increased in active Crohn's disease, Gastroenterology 1994; 106 (suppl): A712.
24. Bjarnason I, Li F, Buxton-Thomas M, Forgacs I, Moniz C, Macpherson A. Mechanism of osteoporosis in patients with inflammatory bowel disease. Gastroenterology 1994; 106 (suppl): A652.
25. Oikarinen A, Autio P, Vuori J, Väänänen K, Risteli L, Kiistala U, et al. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol 1992; 126; 172-8.